SCHEMBL6417708

SCHEMBL6417708

CCOc1ccccc1N(CCN1CCN(c2cccc(NC(=O)C3=CCCN(C)C3)c2)CC1)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.43
TP53 P04637 2/20 0.43
HTR7 P34969 3/20 0.40
HTR1A P08908 3/20 0.40
DRD2 P14416 2/20 0.39
ADRA1A P35348 1/20 0.39
DRD3 P35462 1/20 0.39
HSD17B10 Q99714 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 1/20 0.39
TSHR P16473 1/20 0.39
EGFR P00533 1/20 0.39
ERBB2 P04626 1/20 0.39
KMT2A Q03164 1/20 0.39
ALOX15 P16050 1/20 0.38
ALOX12 P18054 1/20 0.38
NR4A1 P22736 1/20 0.38
FGFR3 P22607 1/20 0.38
PKM P14618 1/20 0.38
HTR1D P28221 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5654667 0.86 HTR7 (0.53) MAPTTP53HTR7HTR1AHTR2A
SCHEMBL5655916 0.84 MAPT (0.50) MAPTTP53HTR1ADRD2ADRA1A
SCHEMBL6416890 0.84 DRD2 (0.52) MAPTTP53DRD2ADRA1ADRD3
SCHEMBL6415441 0.83 MAPT (0.52) MAPTTP53HTR7HTR1ADRD2
SCHEMBL6189802 0.82 DRD2 (0.45) MAPTTP53HTR7HTR1ADRD2
SCHEMBL5656008 0.81 HTR7 (0.54) MAPTTP53HTR7HTR1ADRD2
SCHEMBL5657837 0.80 HTR1A (0.56) MAPTHTR7HTR1ADRD2ADRA1A
SCHEMBL5657971 0.80 KCNH2 (0.50) MAPTHTR7HTR1ADRD2DRD3
SCHEMBL5657779 0.80 HTR1A (0.59) MAPTHTR7HTR1ASMN1; SMN2TSHR
SCHEMBL5656134 0.80 HTR1A (0.48) MAPTHTR7HTR1AADRA1ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050267126-A1 Compounds derived from aryl carbamates, preparation thereof and uses of same CEREP (FR) 2005-12-01 US claimed
US-20050267126-A1 Compounds derived from aryl carbamates, preparation thereof and uses of same CEREP (FR) 2005-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267126-A1 Compounds derived from aryl carbamates, preparation thereof and uses of same HTR4, HTR2B, HTR1B MAPT 3281/4885TP53 4475/4885HTR7 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.